On August 24, 2026, the FDA sent warning letters to Royal Peptides LLC, NuScience Peptides LLC and Peptide Partners LLC. Each shop carried research-use language. In each letter, the FDA looked past it.
The disclaimer
The FDA used nearly the same words all three times. To Peptide Partners: “Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”
What outweighed it
First, what the pages said. The FDA quoted lines written as research summaries, such as this one from Peptide Partners: “This laboratory study . . . suggests that semaglutide could have potential benefits for bone health…” In the NuScience letter, it even quoted a PubChem page it said was linked from the shop’s product page.
Second, what was sold together. All three letters mention bacteriostatic water. In the NuScience and Peptide Partners letters, the FDA listed the water itself as a drug. To Peptide Partners: “The sale of these products together demonstrates that you intend for your ‘Reconstitution Solution (BAC)’ to be used in combination for injection.”
In plain terms
Across the three letters, the FDA read the disclaimer against the whole website: descriptions, articles, links, tools and product pairings. The letters do not say what the companies did afterward.
Alexios reviews a shop’s website for the kinds of wording and product pairings described in these letters, before the shop applies to take card payments. A review does not guarantee any outcome with the FDA or with a payment company.
This article describes public FDA letters. It is not legal advice.
Sources
- FDA warning letter, Royal Peptides LLC, reference 734884, dated August 24, 2026, posted September 1, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
- FDA warning letter, NuScience Peptides LLC, reference 733652, dated August 24, 2026, posted September 1, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
- FDA warning letter, Peptide Partners LLC, reference 735063, dated August 24, 2026, posted September 1, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026